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Abstract. An outbreak of cholera began in Haiti in October of 2010. To understand the progression of epidemic cholera
in Haiti, in April of 2012, we initiated laboratory-enhanced surveillance for diarrheal disease in four Haitian hospitals in
three departments. At each site, we sampled up to 10 hospitalized patients each week with acute watery diarrhea. We tested
1,616 specimens collected from April 2, 2012 to March 28, 2013; 1,030 (63.7%) specimens yielded Vibrio cholerae,
13 (0.8%) specimens yielded Shigella, 6 (0.4%) specimens yielded Salmonella, and 63 (3.9%) specimens tested positive
for rotavirus. Additionally, 13.5% of children < 5 years old tested positive for rotavirus. Of 1,030 V. cholerae isolates,
1,020 (99.0%) isolates were serotype Ogawa, 9 (0.9%) isolates were serotype Inaba, and 1 isolate was non-toxigenic
V. cholerae O139. During 1 year of surveillance, toxigenic cholera continued to be the main cause of acute diarrhea in
hospitalized patients, and rotavirus was an important cause of diarrhea-related hospitalizations in children.
INTRODUCTION
In October of 2010, an outbreak of cholera began in Haiti, a
country where cholera cases had not been seen in at least a
century. By November of 2010, toxigenic Vibrio cholerae O1
had been confirmed in all 10 of Haiti’s administrative depart-
ments.1 Cholera treatment facilities (CTFs), semipermanent
facilities often associated with a hospital or health center,
were quickly constructed and staffed to treat cholera patients,
and a National Cholera Surveillance System (NCSS) was
established to collect data on the number of cases, hospitali-
zations, and deaths in CTFs. As of June 30, 2013, 663,134
cholera cases and 8,160 deaths attributed to cholera had been
reported to the NCSS.2,3
Since the beginning of the outbreak, the NCSS has used a
case definition for cholera based on symptoms rather than
laboratory confirmation; the NCSS defines a cholera case as
any patient with three or more episodes of acute watery diar-
rhea within 24 hours. Before March of 2012, the proportion of
syndromic cholera cases reported to the NCSS with laboratory-
confirmed cholera was not systematically evaluated.
In April of 2012, the Haiti National Public Health Labora-
tory (LNSP) and the US Centers for Disease Control and
Prevention (CDC) Haiti established sentinel laboratory-based
surveillance for acute diarrheal illness in Haiti to estimate the
proportion of hospitalized patients at CTFs and hospitals with
laboratory-confirmed cholera, monitor changes in cholera anti-
microbial susceptibility and serotypes, and better understand
the burden of other diarrheal diseases in Haiti.
MATERIALS AND METHODS
We selected four hospitals for surveillance. The first two
hospitals, Hôpital Universitaire La Paix (HUP) and Hôpital
Foyer Saint Camille (HSC), are located in the capital of Haiti,
Port-au-Prince, in West Department. The third site, Hôpital
Saint Nicolas (HSN) de Saint Marc, is in Artibonite Depart-
ment, and the fourth site, Hôpital Saint Michel de Jacmel
(SMJ), is in South East Department. HSC is a privately
funded Catholic institution; the other three hospitals are pub-
lic facilities. We chose these four hospitals because they all
have associated CTFs, are relatively large facilities, and are
located within a 3-hour drive from LNSP in Port-au-Prince,
making transport of specimens manageable.
At each site, we used convenience sampling to collect stool
specimens from up to 10 hospitalized patients per week with
acute watery diarrhea (defined as three or more episodes of
acute watery diarrhea within 24 hours, with onset of symp-
toms within the past 7 days). Nurses were trained to collect
one-half of the weekly specimens from patients < 5 years old.
Patients who had taken antibiotics either at home or in the
health facility were excluded. Hospitalized patients were
selected from CTFs, pediatric wards, medicine wards, and
emergency rooms. Nurses selected patients at different times
of the day and week depending on patient flow and their work
load. We also administered a questionnaire to patients to
collect demographic and clinical information. In September
of 2012, after recognizing that only 18% of patients sampled
were children < 5 years old, we increased the maximum num-
ber of weekly samples to 15 patients at HUP, the hospital with
the highest overall patient volume, in an effort to increase
enrollment of younger children.
Whole stool was collected in a cup, and two swabs were
placed into Cary–Blair transport medium (Becton, Dickinson
and Company, Sparks, MD). Whole stool and inoculated
transport medium were stored at 2–8°C for up to 3 days
before transport to LNSP. At LNSP, specimens were inocu-
lated onto Thiosulfate-Citrate-Bile salts-sucrose (TCBS) agar
(Thermo Scientific™, Remel™, Lenexa, KS), MacConkey
agar (Becton, Dickinson and Company, Sparks, MD), and
Hektoen and Xylose Lysine Deoxycholate (XLD) agar (Becton,
Dickinson and Company, Sparks, MD). Plates were incu-
bated at 37°C for 24 hours, and the appropriate colonies
were selected for additional testing to identify V. cholerae,
Shigella, and Salmonella. Whole-stool specimens collected
before December of 2012 were also tested for V. cholerae
with the Crystal VC Rapid Diagnostic Test (RDT; Span
Diagnostics, Surat, India). Pure cultures of V. cholerae were
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tested by disc diffusion on Mueller–Hinton agar (Becton,
Dickinson and Company, Sparks, MD) without blood and
with ampicillin, tetracycline (as a marker for doxycycline),
and trimethoprim/sulfamethoxazole. Results were interpreted
according to Clinical and Laboratory Standards Institute
(CLSI) guidelines4; 115 isolates were sent to the Enteric
Diseases Laboratory at CDC Atlanta for toxigenicity and
additional antimicrobial susceptibility testing.4,5 All stool
specimens were also tested for rotavirus using Premier
Rotaclone EIA (Meridian Diagnostics, Cincinnati, OH) enzyme
immunoassay (EIA).
Data were entered and stored in a Microsoft Access 2010
database (Microsoft Corporation, Redmond, WA), and ana-
lyzed using SAS 9.3 (SAS, Cary, NC). Descriptive statistics
were generated using frequency procedures, and differences
in proportions were tested using c2 test statistics. Univariate
logistic regression was used to assess whether demographic
factors (e.g., age and sex) were associated with cholera. Fac-
tors that were statistically significant in univariate models
were included in a multivariable model, and two-way interac-
tions were assessed. No interactions were significant at P <
0.05, and only the main effects were included in the final
model. Sex was not included in the final model, because it
was neither significant in a univariate model nor a confounder
in the multiple regression model. Although the patient ques-
tionnaire collected some clinical variables, in this manuscript,
we focus mainly on demographic characteristics of patients;
clinical data will be presented in a separate manuscript.
Only samples positive for V. cholerae by culture were con-
sidered confirmed. The sensitivity and specificity of the Crys-
tal VC RDT were evaluated using cholera culture as the gold
standard. The CDC determined this surveillance activity to be
non-research, and therefore, approval was not required from
the CDC Institutional Review Board. The Haiti Ethical
Review Committee also considered this activity to be non-
research. Verbal consent was obtained from adults and the
parents or guardians of minors.
RESULTS
From April 2, 2012 to March 28, 2013, we collected stool
specimens from 1,616 patients at the four sites. Almost one-
half (47.1%) of the specimens were from females. The
median age was 25 years (range = < 1 month to 95 years),
and 319 (20.0%) patients were under 5 years (Table 1). The
highest percentage of patients was from HUP (35.2%),
whereas the lowest percentage was from HSC (20.5%). Most
patients (84.5%) were treated in CTFs, whereas 12.2% of
patients were from pediatric wards; only 3.4% of patients were
enrolled from the emergency room or medical wards. Enrolled
patients had a mean of 14.4 stools/day, and 56.9% of patients
were severely dehydrated.
Of 1,616 specimens tested by culture, 1,030 (63.7%) speci-
mens yielded V. cholerae, 6 (0.4%) specimens yielded Salmo-
nella, and 13 (0.8%) specimens yielded Shigella. By EIA,
63 (3.9%) specimens tested positive for rotavirus. Four speci-
mens were positive for both V. cholerae and rotavirus. One
specimen yielded V. cholerae, Salmonella, and Shigella. No
other coinfections were documented. A greater percentage
of patients over 18 years (73.4%) and between 5 and 17 years
(70.6%) tested positive for cholera compared with patients
2–4 (48.7%) and under 2 years (13.4%; P < 0.0001) (Table 1).
The proportion of children under 5 years who were treated
in pediatric wards and tested positive for cholera was lower
than the proportion of children under 5 years treated in
CTFs who were positive for cholera (6.1% versus 55.6%,
P < 0.0001). The monthly proportion of specimens among
patients 5 years and older that tested positive for cholera
ranged from 47% to 83% (Figure 1). The proportion was
highest from May to June and from November to December
of 2012. Among patients under 5 years old, the proportion
ranged from 6% to 52%, and it was highest in May and
December of 2012 (Figure 2).
Results from unadjusted logistic regression models showed
that age, hospital site, and hospital ward were all associated
Table 1
Demographic characteristics of patients with acute diarrhea in Haiti from April 2, 2012 to March 28, 2013
Overall (N = 1,616) Cholera (N = 1,616) Shigella (N = 1,616) Salmonella (N = 1,616) Rotavirus (N = 1,616)
No pathogen detected
(N = 1,616)
n % n % n % n % n % n %
Total 1,030 63.7 13 0.8 6 0.4 63 3.9 517 40.0
Demographics*
Age (years)
0–1 202 12.6 27 13.4 2 1.0 0 0.0 31 15.4 143 70.8
2–4 117 7.3 57 48.7 0 0.0 1 0.9 12 10.3 50 42.7
5–17 231 14.5 163 70.6 2 0.9 1 0.4 9 3.9 59 25.5
18–65 957 59.9 707 73.9 9 0.9 3 0.3 8 0.8 233 24.4
65 and older 92 5.8 63 68.5 0 0.0 0 0.0 0 0.0 29 31.5
Sex
Male 853 52.9 540 63.3 7 0.8 5 0.6 31 3.6 276 32.4
Female 759 47.1 487 64.2 6 0.8 1 0.1 30 4.0 240 31.6
Hospital
HUP 569 35.2 402 70.7 4 0.7 2 0.4 16 2.8 150 26.4
HSN 381 23.6 219 57.5 6 1.6 2 0.5 19 5.0 140 36.8
SMJ 334 20.7 247 74.0 0 0.0 1 0.3 3 0.9 84 25.2
HSC 332 20.5 162 48.8 3 0.9 1 0.3 23 6.9 143 43.1
Hospital ward
Pediatrics 195 12.2 11 5.6 2 1.0 0 0.0 32 16.1 151 77.4
Emergency/internal medicine 54 3.4 14 25.9 2 3.7 0 0.0 2 3.7 37 68.5
Cholera treatment center 1,356 84.5 1,000 73.8 9 0.7 6 0.4 28 2.1 324 23.9
*Missing information: age (17 patients), sex (4 patients), and hospital ward (11 patients).
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with culture-confirmed cholera (Table 2). In an adjusted
model including age, hospital site, and hospital ward, patients
0–2 years were less likely to have cholera (odds ratio [OR] =
0.27, 95% confidence interval [95% CI] = 0.16–0.46) com-
pared with patients 5 years and older (Table 2). In a model
that adjusted for both age and hospital ward, compared with
patients from HUP, patients from HSN had lower odds of
testing positive for cholera (OR = 0.54, 95% CI = 0.40–0.73).
Diarrheal patients treated in pediatric wards (OR = 0.05, 95%
CI = 0.02–0.10) and emergency and internal medicine wards
(OR = 0.14, 95% CI = 0.07–0.26) were much less likely to
have cholera compared with patients treated in CTFs, even
after adjusting for patient age and hospital.
Of 1,029 V. cholerae serogroup O1 toxigenic isolates,
1,020 (99.0%) isolates were identified as serotype Ogawa,
and 9 (0.9%) isolates were identified as serotype Inaba.
One non-toxigenic isolate was identified as V. cholerae
serogroup O139 by RDT and standard serogroup O139
antisera testing at LNSP. It was later confirmed to be a
non-toxigenic isolate of V. cholerae O139. One-hundred
fifteen isolates were tested for antimicrobial susceptibility
at CDC Atlanta. All isolates were susceptible to ampicil-
lin, and all but six isolates were resistant to trimethoprim-
sulfamethoxazole. One isolate from a patient at HSN showed
intermediate resistance to tetracycline; all others were fully
susceptible to tetracycline.
In total, 741 specimens were tested for cholera by the Crystal
VC RDT. The sensitivity and specificity of the RDT were
95.6% and 79.5%, respectively, and the positive and negative
predictive values were 89.4% and 91.0%, respectively (Table 3).
Rotavirus was identified more frequently in children 0–1
(15.4%) and 2–4 years (10.3%) compared with patients 5–18
Figure 2. Proportion of samples from patients under 5 years positive for V. cholerae by stool culture and rotavirus by month from April 2, 2012
to March 28, 2013.
Figure 1. Proportion of samples from patients 5 years and older positive for V. cholerae by stool culture and rotavirus by month from April 2,
2012 to March 28, 2013.
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(3.9%) and > 18 years (0.8%; P < 0.0001). The proportion of
children under 5 years who were treated in pediatric wards
and tested positive for rotavirus was similar to the proportion
of children under 5 years treated in CTFs who were positive
for rotavirus (15.6% versus 10.2%, P = 0.38). The monthly
proportion of rotavirus among children under 5 years of age
ranged from 0% to 41% (Figure 2). The proportion was
highest in February and March of 2013 and lowest from May
to June of 2012 and from November to December of 2012,
when the percentage of children with V. cholerae was highest.
DISCUSSION
We found that, from 18 to 30 months after the beginning of
the cholera epidemic in Haiti, nearly two-thirds of hospital-
ized diarrheal patients who were sampled at four large health
facilities in Haiti had laboratory-confirmed V. cholerae. These
results improve our understanding of the cholera epidemic in
Haiti; although 104,295 syndromically identified cholera cases
were reported to the NCSS during the 1-year period covered
by this analysis, including 17,677 children under 5 years,2 if
national patterns mirror our findings, 27% of the reported
cases in adults and 74% of the reported cases in children under
5 years may have been caused by other diarrheal diseases.
Nevertheless, the fact that the percentage of monthly adult
cholera cases among all sampled diarrheal cases was almost
always over 50% during our 12-month surveillance period illus-
trates that sustained cholera transmission continues to occur in
Haiti. The consistently high proportion of culture-positive
cholera among diarrheal patients in this 12-month period in
Haiti differs from findings from countries in which cholera has
been endemic for a much longer time, where lower proportions
of diarrheal disease are attributable to cholera during long
periods of the year.6,7 Some of this difference, especially in
adults, may be the result of repeated exposures over a longer
period of endemicity.
In multivariable analysis, we found that patients at HSN
had lower odds of being positive for cholera. Because the
cholera outbreak began in the Artibonite, where HSN is
located, it is possible that higher population immunity in this
area resulted in the lower proportion of cholera cases.
In Haiti, healthcare providers have been instructed to refer
suspected cholera patients to external CTFs, which are
constructed and maintained to reduce the risk of environmen-
tal contamination and nosocomial cholera transmission and
ensure safe waste removal. However, we found that approxi-
mately one-tenth of diarrheal patients treated in the pediatric
wards, medical wards, and emergency rooms of the four hos-
pitals had cholera. This finding illustrates that efforts to triage
cholera patients to external CTFs based on symptoms alone
are not perfect; previous studies have also shown that cholera
cases are difficult to diagnose on clinical grounds alone.8,9
Because some cholera patients will likely continue to be
admitted to regular hospital wards in Haiti, ensuring appro-
priate infection control practices in all hospital wards is nec-
essary to prevent cholera transmission within facilities.
In March of 2012, the Haitian National Laboratory char-
acterized two V. cholerae isolates as non-Ogawa serotypes;
these isolates were subsequently confirmed to be serotype
Inaba by CDC Atlanta.10 Previous infection with V. cholerae
serotype Ogawa, the prevailing serotype before March of
2012, confers relatively less immunity to reinfection with
the V. cholerae Inaba serotype. This less-effective cross-
protective immunity raised concerns for an increase in inci-
dence of cholera among previously infected individuals.
However, we did not find evidence of broad serotype con-
version in our sample; only 9 of 1,030 isolates were serotype
Inaba. Additionally, of the isolates tested for antimicrobial
susceptibility, only one isolate was intermediately resistant
to tetracycline, a marker for susceptibility to doxycycline, the
most commonly used antibiotic for treatment of cholera
in Haiti. The close monitoring of antimicrobial susceptibility
can continue to inform clinical cholera treatment guidelines
in Haiti.
In our study, nearly all isolates were serogroup O1, and we
did not identify any non-O1/non-O139 isolates. Our findings
differ from a previous study of cholera patients from Novem-
ber of 2010, a month after the beginning of the cholera out-
break in Haiti, in which non-Ol/non-O139 V. cholerae was
isolated from 21% of patients.11 However, our findings are
consistent with other studies of samples collected from patients
identified later in the Haiti outbreak, which found only
serogroup O1 isolates.12,13 These results are not unexpected;
non-O1/O139 serogroups generally cause a diarrheal dis-
ease that is less severe than cholera and does not have epi-
demic potential, whereas toxigenic O1 and O139 serogroups
have epidemic potential.14
The V. cholerae O139 isolate was initially identified by
culture and agglutination in O139 antiserum. Then, a suspen-
sion of an isolated colony was tested using the Crystal VC
RDT and found to be positive for O139. The isolate was later
confirmed as a non-toxigenic V. cholerae serogroup O139 by
CDC Atlanta. Non-toxigenic O139 is uncommon in the
United States but has been documented in CDC’s Cholera
and Other Vibrio Illness Surveillance System.15 Toxigenic
Table 2
Unadjusted and adjusted results of logistic regression models of






0–2 0.06 (0.04–0.09) 0.27 (0.16–0.46)
2–4 0.36 (0.24–0.52) 0.64 (0.41–1.02)
³ 5 Reference Reference
Hospital
HUP Reference Reference
HSN 0.56 (0.43–0.74) 0.54 (0.40–0.73)
SMJ 1.18 (0.87–1.60) 1.00 (0.71–1.38)
HSC 0.40 (0.30–0.52) 0.93 (0.65–1.34)
Hospital ward
Pediatrics 0.02 (0.01–0.04) 0.05 (0.02–0.10)
Emergency/internal medicine 0.13 (0.07–0.23) 0.14 (0.07–0.26)
Cholera treatment center Reference Reference
Table 3
Sensitivity, specificity, negative predictive value, and positive





Positive 457 54 511
Negative 21 209 230
Total 478 263 741
Sensitivity: 457/478 = 95.6%. Specificity: 209/263 = 79.5%. Positive predictive value:
457/511 = 89.4%. Negative predictive value: 209/230 = 91.0%.
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O139 cholera has been imported to the United States
by tourists and seafood, but transmission in the Western
Hemisphere has never been documented.16
In our study, like a previous study in Haiti,17 the Crystal VC
RDT for cholera performed well compared with culture, the
gold standard for cholera diagnosis. In addition to high sensi-
tivity and relatively high specificity, the test had high positive
and negative predictive values. Others studies that have eval-
uated the Crystal VC have found similarly high sensitivity but
lower specificity estimates (49–73%).18–20 In our study, the
rapid test for cholera was performed in a laboratory by
trained technicians. The location and training of the staff
performing the RDT may partly explain the improved test
performance relative to other studies. In settings where the
diagnostic gold standard of culture is not readily available, a
rapid test for cholera can be a reliable alternative for early
confirmation of cholera outbreaks and a trigger for the rapid
resource mobilization necessary for a successful public health
response. Although the Crystal VC RDT can identify both
serogroup O1 and O139 isolates, final confirmation of these
new strains should be done by culture and cholera toxin test-
ing; although the RDT is highly sensitive and very specific,
culture remains the gold standard.
In our sample, 13.5% of diarrheal patients < 5 years old
tested positive for rotavirus. This percentage is lower than
the percentages described in previous studies from other
countries in the region; a surveillance network from Latin
America and the Caribbean region found that, among chil-
dren < 5 years hospitalized for acute diarrhea, the median
percentage positive for rotavirus was 31.5% (range = 24–
47%).21 However, in Haiti, a country in the midst of a cholera
epidemic, the proportion of diarrheal specimens positive for
rotavirus might be expected to be lower, because cholera adds
considerably to the denominator of hospitalized children with
diarrhea. Indeed, in our surveillance system, almost one-half
of specimens from 2- to 4-year-old children were positive
for cholera.
Our findings have several limitations. First, we only
included four hospital sites in three departments of Haiti,
which limits our ability to generalize results to the rest of the
country. Additionally, although we included 10–15 patients
weekly from each site, patients were selected by convenience
sampling and came predominately from CTFs. Therefore, our
results may have been subject to selection bias and may not be
representative of all diarrheal patients at each site or patients
treated at health facilities without CTFs. Furthermore, we
included hospitalized patients only; the NCSS includes hospi-
talized and non-hospitalized patients. Therefore, our patient
population is not representative of all patients reported to the
NCSS. We were not able to estimate the overall burden of
cholera, because we were unable to obtain denominator data
for the catchment area of the hospitals and overall hospital
admissions. Also, although we excluded patients who had
received antibiotics, we failed to identify the etiology of dis-
ease for 35% of patients sampled. To strengthen surveillance
in the future, we plan to add identification of other enteric
pathogens, such as enterotoxigenic Escherichia coli. Although
all four hospitals have backup generators and samples were
transported in cold boxes with freezer packs, it is possible
that, in some instances, some specimens were not consistently
maintained at the correct temperature, which may have
influenced pathogen recovery. Additionally, we did not col-
lect data on patient outcomes in our study, and we are, there-
fore, not able to analyze how outcomes differed by pathogen
or other factors. Finally, although cholera was more com-
monly identified during Haiti’s two rainy seasons and
although rotavirus was more common during the cooler
months of the year, data from several years of surveillance
are needed to better understand the seasonality of rotavirus
and cholera, both of which have been shown to vary by season
in previous studies in other countries.22,23
More than 2 years after the start of the cholera epidemic in
Haiti, in four hospitals in different parts of the country, chol-
era remained the predominant cause of diarrheal-related hos-
pitalizations among adults and an important cause of
hospitalizations for diarrhea among children. Despite lower
case-fatality rates and decreased international attention since
the beginning of the epidemic, cholera continues to impose
significant demands on human and financial resources from
Haiti’s health system. Rotavirus seems to be a smaller but
significant cause of diarrhea in children < 5 years old. The
introduction of rotavirus vaccine planned for later this year
could help reduce diarrheal disease among children in Haiti.
In areas at risk for cholera outbreaks, as the World Health
Organization has recommended, oral cholera vaccine could
be used.24 Ultimately, broad access to safe drinking water
and sanitation in Haiti will be necessary to reduce the large
burden of cholera and other waterborne diseases on the
Haitian population.
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CHOLERA AND ROTAVIRUS IN PATIENTS WITH ACUTE DIARRHEA IN HAITI 645
Haiti. Available at: http://www.mspp.gouv.ht/site/index.php?
option=com_content&view=article&id=120&Itemid=1. Accessed
July 29, 2013.
3. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou
GA, Mintz ED, Steenland MW, Vertefeuille JF, Tappero JW,
2013. Cholera surveillance during the Haiti epidemic—the first
2 years. N Engl J Med 368: 599–609.
4. Clinical and Laboratory Standards Institute, 2005. Methods for
Antimicrobial Dilution and Disk Susceptibility Testing of Infre-
quently Isolated or Fastidious Bacteria; Proposed Guideline.
Wayne, PA: Clinical and Laboratory Standards Institute.
5. Fields PI, Popovic T, Wachsmuth K, Olsvik O, 1992. Use of
polymerase chain reaction for detection of toxigenic Vibrio
choleraeO1 strains from the Latin American cholera epidemic.
J Clin Microbiol 30: 2118–2121.
6. Manna B, Niyogi SK, Bhattacharya MK, Sur D, Bhattacharya
SK, 2005. Observations from diarrhoea surveillance support
the use of cholera vaccination in endemic areas. Int J Infect
Dis 9: 117–119.
7. Chowdhury F, Rahman MA, Begum YA, Khan AI, Faruque AS,
Saha NC, Baby NI, Malek MA, Kumar AR, Svennerholm AM,
Pietroni M, Cravioto A, Qadri F, 2011. Impact of rapid urban-
ization on the rates of infection by Vibrio cholerae O1 and
enterotoxigenic Escherichia coli in Dhaka, Bangladesh. PLoS
Negl Trop Dis 5: e999.
8. Siddique AK, Ahmed S, Iqbal A, Sobhan A, Poddar G, Azim T,
Sack DA, Rahman M, Sack RB, 2011. Epidemiology of rotavi-
rus and cholera in children aged less than five years in rural
Bangladesh. J Health Popul Nutr 29: 1–8.
9. Sur D, Deen JL, Manna B, Niyogi SK, Deb AK, Kanungo S,
Sarkar BL, Kim DR, Danovaro-Holliday MC, Holliday K,
Gupta VK, Ali M, von Seidlein L, Clemens JD, Bhattacharya
SK, 2005. The burden of cholera in the slums of Kolkata, India:
data from a prospective, community based study. Arch Dis
Child 90: 1175–1181.
10. Centers for Disease Control and Prevention, 2012. Notes from
the field: Identification of Vibrio cholerae serogroup O1, sero-
type Inaba, biotype El Tor strain—Haiti, March 2012. MMWR
Morb Mortal Wkly Rep 61: 309.
11. Hasan NA, Choi SY, Eppinger M, Clark PW, Chen A, Alam M,
Haley BJ, Taviani E, Hine E, Su Q, Tallon LJ, Prosper JB,
Furth K, Hoq MM, Li H, Fraser-Liggett CM, Cravioto A, Huq
A, Ravel J, Cebula TA, Colwell RR, 2012. Genomic diversity
of 2010 Haitian cholera outbreak strains. Proc Natl Acad Sci
USA 109: E2010–E2017.
12. Katz LS, Petkau A, Beaulaurier J, Tyler S, Antonova ES,
Turnsek MA, Guo Y, Wang S, Paxinos EE, Orata F,
Gladney LM, Stroika S, Folster JP, Rowe L, Freeman
MM, Knox N, Frace M, Boncy J, Graham M, Hammer BK,
Boucher Y, Bashir A, Hanage WP, Van Domselaar G,
Tarr CL, 2013. Evolutionary dynamics of Vibrio cholerae
O1 following a single-source introduction to Haiti. MBio
4: e00398-13.
13. Talkington D, Bopp C, Tarr C, Parsons MB, Dahourou G,
Freeman M, Joyce K, Turnsek M, Garrett N, Humphrys M,
Gomez G, Stroika S, Boncy J, Ochieng B, Oundo J, Klena
J, Smith A, Keddy K, Gerner-Smidt P, 2011. Characterization
of toxigenic Vibrio cholerae from Haiti, 2010–2011. Emerg
Infect Dis 17: 2122–2129.
14. Menon M, Mintz ED, Tauxe R, 2009. Bacterial Infections of
Humans, 4th Ed. Berlin: Springer, 255.
15. Centers for Disease Control and Prevention, 2013. Cholera and
Other Vibrio Illness Surveillance System. Available at: http://
www.cdc.gov/nationalsurveillance/cholera_vibrio_surveillance
.html. Accessed July 29, 2013.
16. Boyce TG, Mintz ED, Greene KD, Wells JG, Hockin JC, Morgan
D, Tauxe RV, 1995. Vibrio cholerae O139 Bengal infections
among tourists to Southeast Asia: an intercontinental foodborne
outbreak. J Infect Dis 172: 1401–1404.
17. Boncy J, Rossignol E, Dahourou G, Hast M, Buteau J, Stanislas
M, Moffett D, Bopp C, Balajee SA, 2013. Performance and
utility of a rapid diagnostic test for cholera: notes from Haiti.
Diagn Microbiol Infect Dis 76: 521–523.
18. Page AL, Alberti KP, Mondonge V, Rauzier J, Quilici ML, Guerin
PJ, 2012. Evaluation of a rapid test for the diagnosis of cholera
in the absence of a gold standard. PLoS One 7: e37360.
19. Ley B, Khatib AM, Thriemer K, von Seidlein L, Deen J,
Mukhopadyay A, Chang NY, Hashim R, Schmied W, Busch
CJ, Reyburn R, Wierzba T, Clemens JD, Wilfing H, Enwere G,
Aguado T, Jiddawi MS, Sack D, Ali SM, 2012. Evaluation of a
rapid dipstick (Crystal VC) for the diagnosis of cholera in Zanzibar
and a comparison with previous studies. PLoS One 7: e36930.
20. Mukherjee P, Ghosh S, Ramamurthy T, Bhattacharya MK,
Nandy RK, Takeda Y, Nair GB, Mukhopadhyay AK, 2010.
Evaluation of a rapid immunochromatographic dipstick kit for
diagnosis of cholera emphasizes its outbreak utility. Jpn J
Infect Dis 63: 234–238.
21. de Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipis
AM, Gentsch J, Matus CR, Widdowson MA, Rotavirus Sur-
veillance N, 2009. Sentinel hospital surveillance for rotavirus
in Latin American and Caribbean countries. J Infect Dis 200
(Suppl 1): S131–S139.
22. Patel MM, Pitzer VE, Alonso WJ, Vera D, Lopman B, Tate J,
Viboud C, Parashar UD, 2013. Global seasonality of rotavirus
disease. Pediatr Infect Dis J 32: e134–e147.
23. Pascual M, Bouma MJ, Dobson AP, 2002. Cholera and cli-
mate: revisiting the quantitative evidence. Microbes Infect 4:
237–245.
24. World Health Organization, 2010. Cholera Vaccines: WHO
Position Paper. Geneva: World Health Organization, 117–128.
646 STEENLAND AND OTHERS
